Stay informed on the management of chronic myeloid leukemia (CML). This Expert Review features a discussion and downloadable slides focusing on recent updates in CML. Discussion focuses on the options for first-line treatment of CML, options for sequencing the approved tyrosine kinase inhibitors (TKIs), and how comorbidities and adverse events influence treatment decisions.
Jul 28, 2017
Jul 28, 2018
Elias Jabbour, MDThe University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
François-Xavier Mahon, MD, PhDInstitut Bergonié
- Front-line treatment of CML
- Sequencing TKIs in CML
- Common adverse events associated with TKIs
- The role of comorbidities in selecting appropriate treatment of CML
This educational activity is designed for Ex‐US oncologists, hematologists, and other healthcare professionals involved and/or interested in the management of patients with CML.
After successful completion of this educational activity, participants should be able to:
- Describe the efficacy of second‐generation TKIs for CML therapy in first‐line treatment
- Distinguish the tolerability profiles of available TKIs in order to effectively manage adverse events and select appropriate therapy based on patient preference and underlying comorbidities
- Identify best practices with respect to monitoring responses and when to switch TKI therapy
This educational activity is supported by Pfizer.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.